Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €15.48 EUR
Change Today -0.097 / -0.62%
Volume 0.0
LMX On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 3:54 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

luminex corp (LMX) Snapshot

Open
€15.41
Previous Close
€15.57
Day High
€15.74
Day Low
€15.17
52 Week High
10/10/14 - €16.98
52 Week Low
08/11/14 - €13.05
Market Cap
665.8M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
43.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LUMINEX CORP (LMX)

Related News

No related news articles were found.

luminex corp (LMX) Related Businessweek News

No Related Businessweek News Found

luminex corp (LMX) Details

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics and life sciences industries worldwide. It offers xMAP technology, an open architecture, multiplexing technology that allows simultaneous analysis of approximately 500 bioassays from a drop of fluid by reading biological tests on the surface of microscopic polystyrene beads called microspheres; and MultiCode technology used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays. The company’s products include Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; and MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids. It also offers MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; respiratory viral family of products, including respiratory viral panel to identify the causative agent for respiratory infections; and gastrointestinal pathogen panel family of products, such as in vitro diagnostic (IVD) assays to identify the pathogens causing infectious gastroenteritis. In addition, the company offers MultiCode assays and products comprising HSV1/2 kits, analyte specific reagents, and other products to detect infectious agents in clinical samples; cystic fibrosis family of products comprising IVD kits for cystic fibrosis genotyping; personalized medicine family of products consisting of assays to determine the drug metabolism status; and specialty product family and instrumentation products, as well as operates an original equipment manufacturer of custom reagents and instrumentation. It serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is headquartered in Austin, Texas.

745 Employees
Last Reported Date: 02/25/15
Founded in 1995

luminex corp (LMX) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $275.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $370.8K
Senior Vice President - Research & Developmen...
Total Annual Compensation: $327.0K
Chief Marketing & Sales Officer and Senior Vi...
Total Annual Compensation: $334.3K
Compensation as of Fiscal Year 2014.

luminex corp (LMX) Key Developments

Luminex Corporation Submits FDA 510(k) Submissions for ARIES™ System and ARIES™ HSV 1&2 Assay

Luminex Corporation announced that it has submitted 510(k) applications to the FDA for the company's ARIES™ System and ARIES™ HSV 1&2 Assay. The company anticipates receiving FDA clearance and CE-IVD marking before the end of 2015. Clinical trials for the ARIES C. difficile Assay and the ARIES Group B Streptococcus (GBS) Assay are progressing, and the company expects to launch clinical trials for additional ARIES products prior to the end of 2015.

Enzo Biochem Reaches $7.1 Million Patent Infringement Settlement with Luminex Corporation

Enzo Biochem Inc. announced that it has reached and finalized a settlement with Luminex Corporation involving payment of $7.1 million to Enzo in an infringement action brought by Enzo regarding its U.S. Patents Nos. 6,992,180; 7,064,197; and 8,097,405. Settlement resolving the disputes between Enzo and Luminex impacts only one of 12 cases originally brought by Enzo in the United States District Court for the District of Delaware alleging patent infringements against various companies, the remainder of which are still pending.

Luminex Corporation Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 02:00 PM

Luminex Corporation Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 02:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LMX:GR €15.48 EUR -0.097

LMX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Computer Programs & Systems Inc $46.77 USD -7.48
HealthStream Inc $28.06 USD +0.21
Merge Healthcare Inc $5.49 USD -0.01
Meridian Bioscience Inc $18.09 USD -0.09
Quidel Corp $20.71 USD -0.25
View Industry Companies
 

Industry Analysis

LMX

Industry Average

Valuation LMX Industry Range
Price/Earnings 18.0x
Price/Sales 3.2x
Price/Book 2.2x
Price/Cash Flow 16.7x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUMINEX CORP, please visit www.luminexcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.